WO2024184796 - SUSTAINED RELEASE SOLID ORAL BOLUS
National phase entry:
Publication Number
WO/2024/184796
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052090
International Filing Date
04.03.2024
Title **
[English]
SUSTAINED RELEASE SOLID ORAL BOLUS
[French]
BOLUS ORAL SOLIDE À LIBÉRATION PROLONGÉE
Applicants **
WELFARE CONCEPTS LIMITED
Inventors
ALAWI, Fadil
NANJAN, Karthigeyan
OLDE RIEKERINK, Richard Gerhardus Martinus
EMSLIE, Forbes Richard
Priority Data
2023900580
06.03.2023
AU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3186 | |
| EPO | Filing, Examination, Granting | 26504 | |
| Japan | Filing, Examination, Granting | 3017 | |
| South Korea | Filing, Examination, Granting | 3746 | |
| USA | Filing, Examination, Granting | 12540 |
Total:
48,993
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A sustained release solid oral bolus that, once ingested, is capable of providing sustained release of a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID), and its use for treating fever, pain and/or inflammation, preferably caused by periparturient disorders, such as mastitis, lameness, endometritis, metritis, or subfertility.[French]
L'invention concerne un bolus oral solide à libération prolongée qui, une fois ingéré, est capable de fournir une libération prolongée d'une quantité thérapeutiquement efficace d'un médicament anti-inflammatoire non stéroïdien (AINS), et son utilisation pour le traitement de la fièvre, de la douleur et/ou de l'inflammation, de préférence provoquées par des troubles périnataux, tels que la mastite, la boiterie, l'endométrite, la métrite ou l'hypofertilité.